Device center studying adverse events related to children
This article was originally published in The Silver Sheet
Executive Summary
CDRH is conducting an in-depth study of adverse events with medical devices in younger patients, the first part of which was published online July 26 in the journal Pediatrics. FDA staffers analyzed visits to 100 U.S. emergency rooms between Jan. 1, 2004, and Dec. 21, 2005, by patients 21 years old or younger. Most device-related adverse events involve Class II, moderate-risk devices, according to results presented in the article. The 144,799 identified events involved devices from 13 medical specialties, including ophthalmology, cardiology and radiology, but the researchers concluded that it was two product categories that primarily contributed to the public health burden: ophthalmic devices - notably contact lenses - and physical medicine devices
You may also be interested in...
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.